Our research shows the transformative effect that alemtuzumab can have for people with MS.
Patients who continue to show disease activity while on their initial therapy are especially difficult to treat.
Now, we have shown that alemtuzumab works where first-line drugs have already failed.
It not only reduces the chances of disability associated with MS but may even result in long-term clinical improvements.
More top news
Rain will spread southeastwards through N. Ireland, Wales and England overnight. Northern parts of Britain will remain mostly dry.
Two members of the public were injured along with two police officers who were in the unmarked vehicle.
One of the attackers who murdered a priest in a French church during morning mass in Normandy has been named by prosecutors.